A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with dabrafenib and trametinib evidenced by an algorithm-defined pyrexia score

Pyrexia is a frequent adverse event of BRAF/MEK-inhibitor combination therapy in patients with metastasized malignant melanoma (MM). The study’s objective was to identify laboratory changes which might correlate with the appearance of pyrexia. Initially, data of 38 MM patients treated with dabrafeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaefer, Hannah, Rübben, Albert, Esser, André, Araujo, Arturo, Persa, Oana-Diana, Leijs, Marike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409555/
https://www.ncbi.nlm.nih.gov/pubmed/36006943
http://dx.doi.org/10.1371/journal.pone.0273478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409555/
https://www.ncbi.nlm.nih.gov/pubmed/36006943
http://dx.doi.org/10.1371/journal.pone.0273478

Ejemplares similares